A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M-3 selective receptor antagonist, in the treatment of overactive bladder

C. Chapple, W. Steers, P. Norton, R. Millard, G. Kralidis, K. Glavind, P. Abrams

Research output: Contribution to journalJournal articleResearchpeer-review

114 Citations (Scopus)
Original languageEnglish
JournalBJU International
Pages (from-to)993-1001
Number of pages9
Publication statusPublished - 2005
Externally publishedYes

Cite this